Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 8c; Net R&D Expenses Halved
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BrainStorm Announces Financial Results for 2015 and Provides Business Update
March 10, 2016 7:42 AM ESTHACKENSACK, N.J. and PETACH TIKVAH, Israel, March 10, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2015.  Brainstorm filed its annual report on Form 10-K reporting the results on March 9, 2016.
"2015 was a year of continued progress and momentum for Brainstorm," stated Chaim Lebovits, Chief Executive Officer of BrainStorm. "We achieved a number of important milestones including completion... More
